References
- Chen YT, Feng B, Chen LB (2012). Update of research on drug resistance in small cell lung cancer chemotherapy. Asian Pac J Cancer Prev, 13, 3577-81. https://doi.org/10.7314/APJCP.2012.13.8.3577
- De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al (2006). Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small cell lung cancer. J Clin Oncol, 24, 1057-63. https://doi.org/10.1200/JCO.2005.02.9793
- De Ruysscher D, Paris E, Le Pechoux C, et al (2011). A metaanaysis of randomized trials using individual patient data on the timing of chest radiotherapy in patients with limited stage small cell lung cancer. J Thorac Oncol, 6, S641-2. https://doi.org/10.1097/JTO.0b013e3182037c80
- Erridge SC, Murray N (2003). Thoracic radiotherapy for limitedstage small cell lung cancer: issues of timing, volumes, dose, and fractionation. Semin Oncol, 30, 26-37.
- Fried DB, Morris DE, Poole C, et al (2004). Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small cell lung cancer. J Clin Oncol, 22, 4837-45. https://doi.org/10.1200/JCO.2004.01.178
- Govindan R, Page N, Morgensztern D, et al (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44. https://doi.org/10.1200/JCO.2005.04.4859
- Huncharek M, McGarry R (2004). A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist, 9, 665-72. https://doi.org/10.1634/theoncologist.9-6-665
- Intaraphet S, Kasatpibal N, Siriaunkgul S, et al (2013). Prognostic impact of histology in patients with cervical squamous cell carcinoma, adenocarcinoma and small cell neuroendocrine carcinoma. Asian Pac J Cancer Prev, 14, 5355-60. https://doi.org/10.7314/APJCP.2013.14.9.5355
- Karam I, Jiang SY, Khaira M, Lee CW, Schellenberg D (2013). Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide. Am J Clin Oncol, (in press).
- Murray N, Coy P, Pater JL, et al (1993). Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 11, 336-44.
- Rossi A, Di Maio M, Chiodini P, et al (2012). Carboplatinor Cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol, 30, 1692-8. https://doi.org/10.1200/JCO.2011.40.4905
- Rossi A, Martelli O, Di Maio M (2013). Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. Cancer Treat Rev, 39, 498-506. https://doi.org/10.1016/j.ctrv.2012.09.006
- Oguz A, Unal D, Tasdemir A (2013). Lack of any association between blood groups and lung cancer independent of histology. Asian Pac J Cancer Prev, 14, 453-6. https://doi.org/10.7314/APJCP.2013.14.1.453
- Spiro SG, James LE, Rudd RM, et al (2006). Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer. A London lung cancer group multicenter randomized clinical trial and metaanalysis. J Clin Oncol, 24, 3823-30. https://doi.org/10.1200/JCO.2005.05.3181
- Sun JM, Ahn YC, Choi EK, et al (2013). Phase III trial of concurrent thoracic radiotherapy with either first- or thirdcycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol, 24, 2088-92. https://doi.org/10.1093/annonc/mdt140
- Takada M, Fukuoka M, Kawahara M, et al (2002). Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol, 20, 3054-60. https://doi.org/10.1200/JCO.2002.12.071
- Turrisi AT 3rd, Kim K, Blum R, et al (1999). Twice-daily compared with once-daily thoracic radiation therapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med, 340, 265-71. https://doi.org/10.1056/NEJM199901283400403
- Warde P, Payne D (1992). Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol, 10, 890-5.
- Wu C, Li F, Jiao SC (2012). Prognostic factors for survival of patients with extensive stage small cell lung cancer-a retrospective single institution analysis. Asian Pac J Cancer Prev, 13, 4959-62. https://doi.org/10.7314/APJCP.2012.13.10.4959
- Yee D, Hanson J, Butts C, et al (2010). Phase I dose escalation trial of hypofractionated limited-field external beam thoracic radiotherapy for limited-stage small cell carcinoma for the lung. Radiother Oncol, 96, 78-83. https://doi.org/10.1016/j.radonc.2010.05.013
- Zhao H, Gu J, Hua F, et al (2010). A meta-analysis of the timing of chest radiotherapy in patients with limited-stage small cell lung cancer. Zhongguo Fei Ai Za Zhi, 13, 892-7.
- Zhao X, Sun X, Li Xl (2012). Expression and clinical significance of STAT3, P-STAT3, and VEGF-C in small cell lung cancer. Asian Pac J Cancer Prev, 13, 2873-7. https://doi.org/10.7314/APJCP.2012.13.6.2873